Neurona Therapeutics Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2008

Location

San Francisco CA US

Primary Industry

Biotechnology

About

Based in California, US, and founded in 2008 by co-founder and CEO Cory R. Nicholas, Neurona Therapeutics, Inc., a.k.a. Neurona Therapeutics is a clinical-stage biotherapeutics company that focuses on the development of cell-based therapeutics and treatment devices for neurological diseases and disorders. Neurona Therapeutics, Inc. raised venture funding from Ysios Capital Partners. In February 2024, Neurona Therapeutics Inc. raised USD 120 million in Series E funding co-led by Viking Global Investors and Cormorant Asset Management, with participation from LYFE Capital, Willett Advisors, Schroders Capital, Euclidean Capital, Spur Capital Partners, UC Investments, Ysios Capital Partners, SymBiosis Capital Management, Alexandria Venture Investments, Berkeley Frontier Fund, The Column Group, UCB Ventures, and Sphera Funds Management. The series A funding values Neurona Therapeutics Inc. at USD 235.42 million post-money. Neurona Therapeutics specializes in developing neural cell therapies for chronic neurological disorders. The company’s primary product, NRTX-1001, consists of inhibitory GABAergic interneurons derived from pluripotent stem cells. NRTX-1001 is also being studied for its potential benefits in Alzheimer's disease by repairing neural activity and improving cognition. This therapy addresses drug-resistant focal epilepsy by enhancing GABAergic inhibition to reduce seizure activity. The company plans to use its proceeds from February 2024 funding to advance its pipeline of cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001.

Current Investors

The National Institutes of Health, California Institute for Regenerative Medicine, South Carolina Research Authority

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.neuronatherapeutics.com

Verticals

Manufacturing

Company Stage

Series E

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.